標題：Research Grade Vatreptacog alfa對照抗體,AntibodySystem Laboratories
鏈接：https://www.antibodysystem.com/product/19169.html
名稱：Research Grade Vatreptacog alfa對照抗體
別名：rFVIIa analog NN1731, FVIIa DVQ, Eptacog Alfa
貨號：DHC35901
適用物種：Human
存儲緩沖區(qū)：0.01M PBS, pH 7.4.
濃度：1 mg/ml
形式：Liquid
純度：>95%
克隆：Monoclonal
同型：A recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions (Asp158Val, Val296Glu, and Glu298Met).
應用：Research Grade Biosimilar
靶點：F7, Proconvertin, SPCA, Serum prothrombin conversion accelerator, Coagulation factor VII, Eptacog alfa
內(nèi)毒素水平：Please contact with the lab for this information.
UniProt：P08709
用途范圍：僅用于科研
儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757
郵箱：biolab-reagents@atagenix.com
QQ：2663991332
參考文獻：
Vatreptacog alfa from conception to clinical proof of concept. PMID: 22510860
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. PMID: 22470921
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. PMID: 26362483
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. PMID: 24931322
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. PMID: 21681082
The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity. PMID: 37915568
Hemostatic properties of the FVIIa analog NN1731. PMID: 22446168
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. PMID: 31506285
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. PMID: 22757678
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. PMID: 28077675
The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. PMID: 29758051
